ArticleScientific reports2025
The effect of cinnamon bark oil in bilateral common carotid artery occlusion-induced cerebral ıischemia model in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Naringenin protects against renal ischemia-reperfusion injury following unilateral nephrectomy via modulation of oxidative stress and kisspeptin expression.International urology and nephrology · 2026Article
- N-acetyl cysteine amide mitigates oxidative stress and apoptosis in a rat model of renal ischemia-reperfusion injury.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to evaluate the protective and therapeutic effects of Cinnamon Bark Oil (CBO) on cerebral ischemia/reperfusion (I/R) injury in rats. The focus was on its potential antioxidant, anti-inflammatory, and antiapoptotic properties. Forty-four female Wistar albino rats were divided into four groups: Sham + CBO group, I/R + Vehicle group, prophylactic (CBO + I/R) group and therapeutic (I/R + CBO) group. Bilateral common carotid artery occlusion was performed to induce ischemia, followed by reperfusion for 72 h. CBO (100 mg/kg) was administered orally. Biochemical, histopathological, and immunohistochemical analyses were conducted, measuring oxidative stress markers, inflammatory cytokines, and neuronal degeneration in the cerebral cortex and hippocampus. Histopathological analysis revealed that CBO significantly reduced neuronal degeneration in both the prophylactic and therapeutic groups. Biochemically, CBO increased superoxide dismutase (SOD) and total antioxidant capacity (TAC), while decreasing malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α) levels. Immunohistochemical staining showed decreased apoptotic markers (caspase-3, Bax) in the prophylactic and therapeutic groups. CBO demonstrated neuroprotective effects in cerebral I/R injury through its antioxidant, anti-inflammatory, and antiapoptotic properties. These findings suggest its potential as a complementary therapeutic agent for ischemic brain injuries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.